AMENDMENTS TO THE CLAIMS

Please cancel claims 16-26 without prejudice.

1. (Currently amended) A fluorogenic composition for the detection of the activity of a protease, said composition having the formula:

~~$F_1-aa^1_j-(aa^2-aa^3)_k-aa^4_l-aa^5-X_m-P-Y_n-aa^6-aa^7_o-(aa^8-aa^9)_p-aa^{10}_q-F_2$~~

~~$(S^1)_i$ $(S^2)_r$~~

$F^1-aa^1_j-(aa^2-aa^3)_k-aa^4_l-aa^5-X_m-P-Y_n-aa^6-aa^7_o-(aa^8-aa^9)_p-aa^{10}_q-F^2$

$(S^1)_i$ $(S^2)_r$

wherein, P has the sequence ~~is a peptide selected from the group consisting of DEVDGIN (SEQ ID NO:196), (d-O)DEVDGIN (SEQ ID NO:197), DEVDGID (SEQ ID NO:198), LVEIDNG (SEQ ID NO:199), GIETESGV (SEQ ID NO:200), TGRT (SEQ ID NO:201), VMTGRT (SEQ ID NO:202), SEVKLDAEF (SEQ ID NO:203), S(d-E)VK(d-L)DAE(d-F) (SEQ ID NO:204), EDVVCCS (SEQ ID NO:205), EEVEGIN (SEQ ID NO:206), D(d-F)VDGIN (SEQ ID NO:207), (d-D)EV(d-D)GIN (SEQ ID NO:208), LVEIENG (SEQ ID NO:209), GIETDSG (SEQ ID NO:210), GIETESG (SEQ ID NO:211), LEHDGIN~~ Leu-Glu-His-Asp-Gly-Ile-Nlu (SEQ ID NO:212), ~~LETDGIN (SEQ ID NO:213), WEHDGIN (SEQ ID NO:214), YVHDG (SEQ ID NO:215), YVHDGIN (SEQ ID NO:216), YVHDA (SEQ ID NO:217), TGRTG (SEQ ID NO:218), S(d-E)VK(d-L)DAE(d-F) (SEQ ID NO:219), IEPDS (SEQ ID NO:220), PLGIAGI (SEQ ID NO:221), SQNYPIVQ (SEQ ID NO:222)~~;

F^1 and F^2 are fluorophores and F^1 is attached to the amino terminal amino acid and F^2 is attached to the carboxyl terminal amino acid;

S^1 and S^2, when present, are peptide spacers ranging in length from 1 to about 50 amino acids and S^1, when present, is attached to the amino terminal amino acid and S^2, when present, is attached to the carboxyl terminal amino acid;

i, j, k, l, m, n, o, p, q, and r are independently 0 or 1;

aa^1 and aa^{10} are independently selected from the group consisting of lysine, ornithine and cysteine;

aa^2, aa^3, aa^8, and aa^9 are independently selected from the group consisting of ~~an amino acid or a dipeptide consisting of~~ Asp, Glu, Lys, Ornithine, Arg, Citulline, homocitrulline, Ser, homoserine, Thr, and Tyr;

aa^5, aa^4, aa^6, and aa^7 are independently selected from the group consisting of proline, 3,4-dehydroproline, hydroxyproline, alpha aminoisobutyric acid and N-methyl alanine;

X is selected from the group consisting of Gly, βAla, γAbu ,Gly-Gly, Ahx, C7, βAla-Gly, βAla-βAla, γAbu-Gly, βAla-γAbu, Gly-Gly-Gly, γAbu-γAbu, Ahx-Gly, βAla-Gly-Gly, Ahx-βAla, βAla-βAla-Gly, Gly-Gly-Gly-Gly (SEQ ID NO:223), Ahx-γAbu, βAla-βAla-βAla, γAbu-βAla-Gly, γAbu-γAbu-Gly, Ahx-Ahx, γAbu-γAbu-βAla, and Ahx-Ahx-Gly;

Y is selected from the group consisting of Gly, βAla, γAbu, Gly-Gly, Ahx, C7, Gly-βAla, βAla-βAla, Gly-γAbu, γAbu-βAla, Gly-Gly-Gly, γAbu-γAbu, Gly-Ahx, Gly-Gly-βAla, βAla-Ahx, Gly-βAla-βAla, Gly-Gly-Gly-Gly, γAbu-Ahx, βAla-βAla-βAla, Gly-βAla-γAbu, Gly-γAbu-γAbu, Ahx-Ahx, βAla-γAbu-γAbu, and Gly-Ahx-Ahx;

when i is 1, S^1 is joined to aa^1 by a peptide bond through a terminal alpha amino group of aa^1; and when r is 1, S^2 is joined to aa^{10} by a peptide bond through a terminal alpha carboxyl group of aa^{10}.

2. (Original) The composition of claim 1, wherein the carboxyl terminal amino acid in which the carboxylic acid group is replaced with an amide.

3. (Original) The composition of claim 1, wherein

r is zero; and

aa^{10} has a C-teminal amide group or free carboxylic acid group.

4. (Currently amended) The composition of claim 1, having the ~~an~~ amino acid sequence ~~selected from the group consisting of Fa KDPJGDEVDGINGJPKGY (SEQ ID NO:224), Fm KDPJGDEVDGINGJPkamide (SEQ ID NO:225), Fm KDPJG (d O)DEVDGINGJPKGY (SEQ ID NO:226), Fm KDPJGDEVDGINGPKGY (SEQ ID NO:227), Fm KDPGDEVDGINGJPKGY (SEQ ID NO:228), Fm KDPJGDEVDGIDGJPkamide (SEQ ID NO:229), Fm KDPJGLVEIDNGJPKGY (SEQ ID NO:230), Fm KDPJGIETESGVGJPKGY (SEQ ID NO:231), Fm KDPJTGRTGPKGY (SEQ ID NO:232), Fm DPTGRTGPKGY (SEQ ID NO:233), Fm~

~~KDPVMTGRTGJPKGY (SEQ ID NO:234), Fm KDPTGRTGJPKGY (SEQ ID NO:235), Fm KDPJGTGRTGJPKGY (SEQ ID NO:236), Fm KDPJGTGRTGPKGY (SEQ ID NO:237), Fm KDPGTGRTGPKGY (SEQ ID NO:238), Fm KDPJGSEVKLDAEFGJPKGY (SEQ ID NO:239), Fm KDPJGS (d E])VK (d L])DAE (d F]) GC5PKDDY (SEQ ID NO:240), Fa KDPJGEDVVCCSGJPKGY (SEQ ID NO:241), KDPJGEEVEGINGJPKGY (SEQ ID NO:242), KDPJGD (d F])VDGINGJPKGY (SEQ ID NO:243), KDPJG (d D])EV (d D])GINGJPKGY (SEQ ID NO:244), KDPJGLVEIENGJPKGY (SEQ ID NO:234), KDPJGIETDSGJPKGY (SEQ ID NO:246), KDPJGIETESGJPKGY (SEQ ID NO:247), KDPJGLEHDGINGJPKGY~~ Lys-Asp-Pro-Ahx-Gly-Leu-Glu-His-Asp-Gly-Ile-Nlu-Gly-Ahx-Pro-Lys-Gly-Tyr (SEQ ID NO:248)~~, KDPJGLETDGINGJPKGY (SEQ ID NO:249), KDPJGWEHDGINGJPKGY (SEQ ID NO:250), KDPJGYVHDGJPKGY (SEQ ID NO:251), KDPJGYVHDGINGJPKGY (SEQ ID NO:252), KDPJGYVHDAPKGY (SEQ ID NO:253), KDPJTGRTGJPKGY (SEQ ID NO:254), KDPC3TGRTGPKGY (SEQ ID NO:255), KDPC7TGRTGPKGY (SEQ ID NO:256), KDPC5GS(d E])VK(d L])DAE(d F])GJPKGY (SEQ ID NO:257), KDPJGIEPDSGJPKGY (SEQ ID NO:258), KDPJGPLGIAGIGJPKGY (SEQ ID NO:259), and KDPJGSQNYPIVQGJPKGY (SEQ ID NO:260)~~.

5. (Original) The composition of claim 1, wherein F^1 and F^2 are the same fluorophore.

6. (Currently Amended) The composition of claim 5, wherein said F^1 and F^2 have an excitation wavelength ~~between about~~ in the range of 315 nm ~~and about~~ to700 nm.

7. (Original) The composition of claim 1, wherein the F^1 molecule is attached through either an α-amino group of the aa^1 amino acid or through a side chain amino group of the aa^1 amino acid, or through a sulfhydryl group of a side chain of the aa^1 amino acid.

8. (Original) The composition of claim 1, wherein the F^2 molecule is attached either through a side chain amino group of the aa^{10} amino acid, through a carboxyl group of the aa^{10} amino acid, or through a sulfhydryl group of a side chain of the aa^{10} amino acid.

9. (Original) The composition of claim 1, wherein said fluorophore is selected from the group consisting of rhodamine X, 9-(2,5 (or 2,6)-dicarboxyphenyl)-3,6-bis(dimethylamino)xanthyliumhalide or other anion (TMR), 9-(2,5)-dicarboxyphenyl)-2,7-dimethyl-

3,6-bis(ethylamino)xanthylium halide or other anion (Rh6G), 9-(2,6)-dicarboxyphenyl)-2,7-dimethyl-3,6-bis(ethylamino)xanthylium halide or other anion, 9-(2,5 (or 2,6)-dicarboxyphenyl)-3,6-bisamino-xanthylium halide or other anion (Rh110), 9-(2,5 (or 2,6)-dicarboxyphenyl)-3-amino-6-hydroxy-xanthylium halide or other anion (Blue Rh), carboxytetramethylrhodamine, carboxyrhodamine-X , diethylaminocoumarin, 9-(2,5-dicarboxyphenyl)-3,6-bis-(dimethylamino)xanthylium chloride (5-TMR), 9-(2,6-dicarboxyphenyl)-3,6-bis-(dimethylamino)xanthylium chloride (6-TMR), 9-(2-carboxyphenyl)-2,7-dimethyl-3,6-bis(ethylamino)xanthylium, 9-(2-carboxyphenyl)-3,6-bis(dimethylamino)xanthylium, and 9-(2-carboxyphenyl)-xanthylium.

10. (Original) The composition of claim 1, wherein said composition bears a hydrophobic group.

11. (Original) The composition of claim 4, wherein said composition bears a hydrophobic group.

12. (Original) The composition of claim 11, wherein said hydrophobic group is selected from the group consisting of: Fmoc, 9-fluoreneacetyl group, 1-fluorenecarboxylic group, 9-florenecarboxylic group, and 9-fluorenone-1-carboxylic group, benzyloxycarbonyl, Xanthyl (Xan), Trityl (Trt), 4-methyltrityl (Mtt), 4-methoxytrityl (Mmt), 4-methoxy-2,3,6-trimethyl-benzenesulphonyl (Mtr), Mesitylene-2-sulphonyl (Mts), 4,4=-dimethoxybenzhydryl (Mbh),Tosyl (Tos), 2,2,5,7,8-pentamethyl chroman-6-sulphonyl (Pmc), 4-methylbenzyl (MeBzl), 4-methoxybenzyl (MeOBzl), Benzyloxy (BzlO), Benzyl (Bzl), Benzoyl (Bz), 3-nitro-2-pyridinesulphenyl (Npys), 1-(4,4-dimentyl-2,6-diaxocyclohexylidene)ethyl (Dde), 2,6-dichlorobenzyl (2,6-DiCl-Bzl), 2-chlorobenzyloxycarbonyl (2-Cl-Z), 2-bromobenzyloxycarbonyl (2-Br-Z), Benzyloxymethyl (Bom), t-butoxycarbonyl (Boc), cyclohexyloxy (cHxO),t-butoxymethyl (Bum), t-butoxy (tBuO), t-Butyl (tBu), Acetyl (Ac), and Trifluoroacetyl (TFA).

13. (Original) The composition of claim 12, wherein said hydrophobic group is Fmoc.

14. (Original) The composition of claim 12, wherein said hydrophobic group is Fa.

15. (Original) The composition of claim 12, wherein said hydrophobic group is attached to the amino terminus of the molecule.